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Abstract: A new series of Bis-[thiadiazol-2-yl-tetrahydro-2H-pyrazolo[3,4-d][1,3]thiazole]methanes 7a-h has 
been synthesized by the reaction of arylidine derivative 6 with aryl/alkyl hydrazines.  Chemical structures of all 
the new compounds were established by IR, 
1H, 
13C NMR, MS and elemental data. The compounds 7a-h were 
evaluated  for  their  antibacterial  activity  against  Gram-positive  bacteria  viz.  Bacillus  subtilis  (ATCC  6633), 
Staphylococcus aureus (ATCC 6538p) and Micrococcus luteus (IFC 12708), and Gram-negative bacteria viz. 
Proteus vulgaris (ATCC 3851), Salmonella typhimurium (ATCC 14028) and Escherichia coli (ATCC 25922).  
Amongst  them,  compounds  containing  N-(4-methoxyphenyl)pyrazole  moiety  7c,  N-(3-fluorophenyl)pyrazole 
moiety 7e and N-methylpyrazole moiety 7h showed significant antibacterial activity, almost equal to the activity 
of the standard drug Ampicillin.  Further, these compounds 7a-h were screened for their antifungal activity 
against Candida albicans (ATCC 10231), Aspergillus fumigatus (HIC 6094), Trichophyton rubrum (IFO 9185) 
and Trichophyton mentagrophytes (IFO 40996). Most of these new compounds showed appreciable activity 
against the test fungi, and emerged as potential molecules for further development.  
 
Keywords:bis-[thiadiazol-2-yl-tetrahydro-2H-pyrazolo[3,4-d][1,3]thiazole]methanes;  antibacterial  activity, 
Antifungal activity.  
 
 
1. Introduction 
Thiadiazoles  exhibit  a  broad  spectrum  of  biological  effectiveness  such  as  anti-parkinsonism,
1 
hypoglycaemic,
2  anti-histaminic,
3  anticancer,
4  anti-inflammatory,
5  anti-asthmatic
6  and  anti-
hypertensive.
7  Further, there has been considerable interest in the chemistry of thiazolidin-4-one ring 
system, which is a core structure in various synthetic pharmaceuticals and displaying a broad spectrum 
of biological activities.
8-10 Thiazolidin-4-one ring also occurs in nature; thus actithiazic acid isolated 
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from  streptomyces  strains  exhibits  highly  specific  in  vitro  activity  against  mycobacterium 
tuberculosis.
11  Thiazolidin-4-one derivatives are also known to exhibit diverse bioactivities such as 
anti-convulsant,
12 antidiarrheal,
13 anti-platelet activating factor,
14,15 anti-histaminic,
16,17 anti-diabetic,
18 
cyclooxygenase  (COX)  inhibitory,
19  Ca
2+-channel  blocker,
20  platelet  activating  factor  (PAF) 
antagonist,
21 cardioprotective,
22 anti-ischemic,
23 anti-cancer,
24  tumor necrosis factor-α antagonist
25 and 
nematicidal.
26   Similarly pyrazole and its derivatives could be considered as possible antimicrobial 
agents.
27,28 The other activities include, antidepressant,
29 inhibitors of protein kinase,
30 antiagreegating,
31 
antiarthritic
32 and cerebroprotector.
33  Some aryl pyrazoles were reported to have non-nucleoside HIV-
1 reverse transcriptase inhibitory,
34 COX-2 inhibitory,
35,  36 activator of the nitric oxide receptor and 
soluble guanylate cyclase inhibitory activity.
37 
Based on the wide spectum of biological profile of thiadiazole, thiazolidin-4-one and pyrazoles 
and their importance in pharmaceutical, and biological field, and in continuation of our on going 
research on biologically active heterocycles,
38-43 it was thought of interest to accommodate thiadiazole 
and thiazolidin-4-one, pyrazole moieties in a single molecular frame work to synthesize some new bis-
heterocyclics for enhancing biological activity. 
We have reported some of our work on the synthesis of heterocyclic compounds derived from bis-
salicylic acid; some of these compounds were screened for their antimicrobial activities, and has been 
found potent activities. The biological significance of such compounds impelled us to continue our 
work on the synthesis of new bis-heterocyclic compounds.  For this purpose we use bis-salicylic acid 
as a starting material. The present investigation deals with the synthesis of some of the interesting bis-
thiadiazolyl-pyrazolothiazoles of expected pharmacological action and to study their effect on bacteria 
and fungi. 
.  
2. Results and Discussion  
 
The  compound  1  was  prepared  according  to  the  procedure  described  in  the  literature.
44 
Condensation of compound 1 with chloroacetone in the presence of K2CO3 and a catalytic amount of 
KI  at  reflux  for  12  h  followed  by  cyclization  in  alc.  KOH  at  reflux  for  18  h  gave  the  bis-[3-
methylbenzo[b]furan-7-carboxylic acid]methane 2 in 72% yield. Further, condensation of compound 2 
with thiosemicarbazide in ethanol at efflux for 10 h, followed by cyclization in conc. H2SO4 at room 
temperature afforded the bis-[5-(3-methylbenzo[b]furan-7-yl)-1,3,4-thiadiazol-2-amine]methane 3 in 
78% yield (Scheme 1). 
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Reagents and conditions: (i) Acetone, K2CO3, KI, reflux 12 h, alc.KOH, reflux 18 h, 72%; (ii) EtOH, reflux 10 h, Conc. H2SO4, rt ,78%. 
 
Scheme 1. Synthetic pathway for compound 3. 
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The compound 3 on reaction with 4-methylbenzaldehyde in the presence of acetic acid at reflux 
for 3 h, furnished the corresponding bis-[N-[5-(3-methylbenzo[b]furan-7-yl)-1,3,4-thiadiazol-2-yl]-N-
[(E)-1-(4-methylphenyl)methyllidene]amine]methane  4  in  74%  yield.  Compounds  4  when  reacted 
with thioglycolic acid in the presence of ZnCl2 in DMF at reflux temperature for 6 h, afforded the bis-
[3-[5-(3-methylbenzo[b]furan-7-yl)-1,3,4-thiadiazol-2-yl]-2-(4-methylphenyl)-1,3-thiazolan-4-one] 
methane 5 in 71% yield (Scheme 2). 
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Reagents and conditions: (iii) AcOH, reflux 3 h, 74%; (iv) DMF, ZnCl2, reflux 6 h, 71%. 
 
Scheme 2. Synthetic pathway for compound 5. 
 
The compound 5 on  reaction with the 4-methylbenzaldehyde in presence of anhydrous NaOAc in 
glacial AcOH at reflux tempereature for 6 h, to gave the bis-[3-[5-(3-methylbenzo[b]furan-7-yl)-1,3,4-
thiadiazol-2-yl]-2-(aryl)-5-[(Z)-1-(aryl)methylidene]-1,3-thiazolan-4-one]methane    6  in  82%  yield. 
Further, the compound 6 on cyclocondensation with hydrazine or aryl/alkyl hydrazines in the presence 
of  anhydrous  NaOAc  in  glacial  AcOH  at  reflux  temperature  for  8  h,  gave  bis-[thiadiazol-2-yl-
tetrahydro-2H-pyrazolo[3,4-d][1,3]thiazole]methanes  7a-h  in  67-76%  yield  (Scheme  3).  The 
versatility of the reaction is well demonstrated by the fact that a variety of aryl/alkyl hydrazines with 
electron-releasing and electron-withdrawing substituents afforded their corresponding compounds 7a-
h in good yields. The structures of all the newly synthesized compounds were confirmed by elemental 
analysis, IR, 
1H NMR, 
13C NMR and MS spectral data. 
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7: R = (a) H; (b) C6H5; (c) 4-CH3O-C6H4; (d) 4-Cl-C6H4; (e) 3-F-C6H4; (f) C6H4-CH2; (g) isopropyl; (h) methyl 
 
Reagents and conditions: (v) AcOH/NaOAc, reflux 6 h, 82%; (vi) R-NH-NH2.HCl AcOH/NaOAc, reflux 8 h, 67-76%. 
 
 
Scheme 3. Synthetic pathways for compounds  7a-g. 
 
 
In the IR spectra of compounds 7a, disappearance of amide carbonyl (C=O) absorption band at 
1720 cm
-1, which was present in compounds 6, confirm the cyclization involving  α,β-unsaturated 
carbonyl system, and the bands at 1360 cm
-1 characteristic for N–C–S bending vibrations provided 
confirmatory evidence for ring closure.  In addition, the absorption band corresponding to C=N of the 
pyrazole moiety was observed at 1604 cm
-1.  Further, support was obtained from the 
1H NMR spectra, 
the N–CH–S proton of thiazole ring appeared at 7.66 ppm, R-CH–N proton of pyrazole ring at 5.18 
ppm as a doublet and S–CH fused proton at 4.31 ppm as a doublet. These signals demonstrate that the 
cyclization step has occurred.  In the 
13C NMR spectra, the prominent signals corresponding to the 
carbons of pyrazolo-thiazole ring in all the compounds observed nearly at 152.4, 67.1, 56.3 and 52.0 
ppm, are proof of further evidence of their structures.  In summary, all the synthesized compounds 
exhibited satisfactory spectral data consistent with their structures. 
 
 
2.1. Antibacterial Activity 
 
All  the  compounds  7a-h  were  assayed  for  their  antibacterial  activity  against  Gram-positive 
bacteria viz. Bacillus subtilis (ATCC 6633), Staphylococcus aureus (ATCC 6538p) and Micrococcus 
luteus  (IFC  12708),  and  Gram-negative  bacteria  viz.  Proteus  vulgaris  (ATCC  3851),  Salmonella 
typhimurium  (ATCC  14028),  and  Escherichia  coli  (ATCC  25922)  by  the  broth  dilution  method, 
recommended by National Committee for Clinical Laboratory Stadards (NCCLs).
45  The bacteria were 
grown over night in Luria Bertani (LB) broth at 37 °C, harvested by centrifugation, and then washed 
twice with sterile distilled water.  Stock solutions of the series of compounds were prepared in DMSO. 
Each  stock  solution  was  diluted  with  standard  method  broth  (Difco)  to  prepare  serial  two-fold 
dilutions in the range of 50 to 0.8 µg/mL.  Ten microliters of the broth containing about 10
5 colony 
forming units (cfu)/mL of test bacteria were added to each well of 96-well microtiter plate. Culture 
plates were incubated for 24 h at 37 °C, and the growth was monitored visually and spectrophoto- 
metrically.  The  lowest  concentration  required  to  arrest  the  growth  of  bacteria  was  regarded  as 
minimum  inhibitory  concentration  (MIC,  µg/mL),  was  determined  for  all  the  compounds  and 
compared with the control.  Amphicillin was also screened under identical conditions for comparison.  61 
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Data of the compounds 7a–h, are presented in Table 1 as the MIC.  It has been observed that the 
compounds exhibited interesting biological activity however, with a degree of variation. 
The investigation of antibacterial screening data revealed that the compound 7c is highly active 
against all the microorganisms employed (except E. Coli) at 1.56 µg/mL concentration; it is almost 
equal to the standard.  Compound 7h is also highly active but only against M. luteus and P. vulgaris at 
the same concentration as 7c. Compound 7e also showed good antibacterial activity against B.subtilis, 
S.  aureus,  M.Luteus  and  S.typhimurium.  Compound  7a  is  almost  inactive  towards  M.  luteus,  P. 
vulgaris and E. coli.  The remaining compounds showed moderate to good activity. 
 
2.2. Antifungal Activity 
 
The compounds 7a-h were also screened for their antifungal activity against Candida albicans 
(ATCC  10231),  Aspergillus  fumigatus  (HIC  6094),  Trichophyton  rubrum  (IFO  9185),  and 
Trichophyton mentagrophytes (IFO 40996) in dimethyl sulfoxide (DMSO) by broth dilution method.
45   
The C. albicans was grown for 48 h at 28 °C in YPD broth (1% yeast extract, 2% peptone, and 2% 
dextrose), harvested by centrifugation and then washed twice with sterile distilled water.  A. fumigatus, 
T. rubrum and T. mentagrophytes were plated in potato dextrose agar (PDA) (Difco) and incubated at 
28 °C for two weeks.  Spores were washed three times with sterile distilled water and resuspended in 
distilled water to obtain an initial inoculum size of 10
5 spores/mL.  Each test compound was dissolved 
in DMSO and diluted with potato dextrose broth (Difco) to prepare serial two-fold dilutions in the 
range of 100 to 0.8 µg/mL.  Ten microliters of the broth containing about 10
3 (for yeast) and 10
4 (for 
filamentous fungi) cells/mL of test fungi was added to each well of a 96-well microtiter plate.  Culture 
plates were incubated for 48 ~ 72 h at 28 °C. Amphotericin B was used as a standard drug and the 
minimum inhibitory concentrations (MIC, µg/mL) were measured and compared with controls, the 
MIC values of the compounds screened are given in Table 2. 
     The  antifungal  screening  data  showed  appreciable  activity  of  the  test  compounds.  Among  the 
screened  compounds,  compound  7c  is  highly  active  against  T.  Rubrum  and  T.  mentagrophytes, 
compound 7e is also active against C. albicans and compound 7h is highly active against C. Albicans 
and  T.  mentagrophytes,  the  activity  of  these  compounds  are  almost  equal  to  the  standard.  It  is 
interesting to note that the compounds 7e and 7h showed good antifungal activity towards C. albicans 
at the concentration of 3.12 µg/mL, which is less than the concentration of the standard. 
 
Table 1. Antibacterial Activity of Compounds 7a-h 
Compound    Minimum Inhibitory Concentration (MIC) in µg/mL 
  B. subtilis  S. aureus  M. luteus  P. vulgaris  S. typhimurium  E. coli 
7a  12.5  12.5  25.0  12.5  25.0  25.0 
7b  6.25  12.5  12.5  6.25  12.5  12.5 
7c  1.56  1.56  1.56  1.56  1.56  6.25 
7d  6.25  6.25  6.25  12.5  25.0  6.25 
7e  3.12  12.5  1.56  1.56  3.12  1.56 
7f  12.5  6.25  3.12  12.5  6.25  12.5 
7g  6.25  25.0  25.0  6.25  50.0  25.0 
7h  12.5  12.5  1.56  1.56  12.5  25.0 
Ampicillin  1.56  1.56  1.56  3.12  3.12  12.5 
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Table 2. Antifungal Activity of Compounds 7a-h 
 
Compound  Minimum Inhibitory Concentration (MIC) in µg/mL 
  C. albicans  A. fumigatus  T. rubrum  T. mentagropytes 
7a  12.5  6.25  25.0  12.5 
7b  12.5  25.0  25.0  25.0 
7c  6.25  6.25  3.12  3.12 
7d  12.5  12.5  6.25  6.25 
7e  3.12  12.5  12.5  25.0 
7f  50.0  12.5  6.25  12.5 
7g  12.5  25.0  6.25  12.5 
7h  3.12  12.5  6.25  3.12 
Amphotericin B  6.25  3.12  3.12  3.12 
 
3. Conclusions 
  
A new  series  of bis-[thiadiazol-2-yl-tetrahydro-2H-pyrazolo[3,4-d][1,3]thiazole]  methanes 7a-h 
has  been  synthesized  and  evaluated  for  their  antimicrobial  activity  against  Gram-positive,  Gram-
negative  bacterial and  fungi. Most of the compounds showed  a moderate degree of antimicrobial 
activity.  Amongst  them  compounds  containing  N-(4-methoxyphenyl)pyrazole  moiety  7c,  N-(3-
fluorophenyl)pyrazole moiety 7e and N-methylpyrazole moiety 7h showed significant antibacterial 
activity, almost equal to the activity of the standard drug ampicillin. Further, these compounds showed 
appreciable  activity  against  the  test  fungi,  and  emerged  as  potential  molecules  for  further 
development.  
4. Experimental 
 
Reagents were of commercial grade and were used as supplied or were prepared according to 
procedures described in literature. Reactions were monitored by thin-layer chromatography (TLC) on 
pre-coated silica gel F254 plates from Merck, and compounds visualized either by exposure to UV 
light. Chromatographic columns 70–230 mesh silica gel for separations were used. Melting points 
were determined on a Fisher–Johns apparatus and are uncorrected. IR spectra were recorded using 
KBr disk on a Perkin–Elmer FTIR spectrometer.  The 
1H NMR, 
13C NMR spectra were recorded on a 
Varian Gemini spectrometer (300 MHz for 
1H and 75 MHz for 
13C).  Chemical shifts are reported in δ 
ppm units with respect to TMS as internal standard and coupling constants (J) are reported in Hz units.  
Mass spectra were recorded on a VG micro mass 7070H spectrometer. Elemental analyses (C, H, N) 
determined by means of a Perkin–Elmer 240 CHN elemental analyzer, were within ± 0.4% of theory. 
 
Synthesis of bis-[3-methylbenzo[b]furan-7-carboxylic acid]methane (2): To a stirred solution 
of  compound  1  (5  mmol),  anhydrous  potassium  carbonate  (3  mmol)  and  a  catalytic  amount  of 
potassium iodide in dry acetone (30 mL), was added drop wise a solution of chloroacetone (10 mmol) 
in dry acetone (20 mL) at reflux temperature.  Reflux was continued for 12 h. The reaction mixture 
was concentrated to dryness, then transferred to ice water, and the solid separated was collected by 
filtration. The crude product was dissolved in ethanolic potassium hydroxide (10%, 100 mL)  and 
further refluxed for 18 h.  The excess ethanol was then removed by distillation in vacuo, the reaction 
mixture was poured into ice-cold aq. HCl and the solid separated was collected by filtration, purified 
by column chromatography using pet-ether (60-80
oC) as eluent to give pure compound 2 as yellow 
solid; yield 72%; m.p. 182-184 
oC; IR (KBr): ν 3400-3300 (COOH), 3037 (C-H, Ar), 1695 (C=O), 
1030 (C-O-C) cm
-1; 
1H NMR (DMSO-d6): δ 9.90 (s, 2H, OH), 7.79 (s, 2H, ArH), 7.65-7.60 (m, 4H, 63 
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ArH), 4.11 (s, 2H, CH2), 2.39 (s, 6H, CH3); 
13C NMR (DMSO-d6): δ 172.6 (C=O), 152.7 (furan-C3b), 
143.9 (furan-C2), 135.2, 132.9 , 132.0 (furan-C3a), 124.6, 121.2, 119.1 (furan-C3), 42.7 (CH2), 9.2 
(CH3); MS: m/z (%) 365 (M
++1, 10), 348 (10), 318 (22), 302 (47), 205 (30), 130 (55), 106 (100%).  
Anal. Calcd for C21H16O8: C, 69.23; H, 4.43. Found: C, 69.18; H, 4.40. 
 
Synthesis of bis-[5-(3-methylbenzo[b]furan-7-yl)-1,3,4-thiadiazol-2-amine]methane (3):  A 
mixture of compound 2 (5 mmol) and thiosemicarbazide (10 mmol) in acetone (20 mL) was refluxed 
for 10 h.  The reaction mixture was allowed to cool, and the solid separated was collected by filtration.  
The crude product was dissolved in conc. H2SO4 (5 mL) and stirred at room temperature for few 
minutes and left overnight.  It was then poured on crussed ice; the resulting suspension was kept in 
ammonical water (25 mL) for 4 h, filtered the solid and recrystallized from ethanol to give pure 
compound 3 as yellow solid; yield 78%; m.p. 192-194 
oC; IR (KBr): ν 3350 (NH2), 3050 (C-H, Ar), 
2985 (C-H, ali), 1605 (C=N), 1030 (C-O-C), 712 (C-H. furan) cm
-1;  
1H NMR (DMSO-d6): δ 7.65-
7.60 (m, 4H, ArH), 7.47 (s, 2H, ArH), 4.92 (s, 4H, NH2), 4.10 (s, 2H, CH2); 
13C NMR (DMSO-d6): δ 
168.2  (thiadiazole-C5),  163.4  (thiadiazole-C2),  153.4  (furan-C3b),  141.7  (furan-C2),  136.1,  130.6 
(furan-C3a), 128.2, 127.1, 123.4, 119.1 (furan-C3), 42.6 (CH2), 9.1 (CH3); MS: m/z (%) 475  (M
++1, 
18%), 459 (27), 436 (33), 421 (31), 392 (40), 334 (49), 302 (75), 130 (47), 102 (100%). Anal. Calcd 
for C23H18N6O2S2: C, 58.21; H, 3.82; N, 17.71.  Found: C, 58.16; H, 3.80; N, 17.69. 
 
Synthesis  of  bis-[N-[5-(3-methylbenzo[b]furan-7-yl)-1,3,4-thiadiazol-2-yl]-N-[(E)-1-(4-
methylphenyl)methyllidene]amine]methane  (4):  A  mixture  of  compound  3  (5  mmol),  4-
methylbenzaldehyde (10 mmol) and acetic acid (0.5 mL) was refluxed in toluene for 3 h using a Dean-
stark apparatus and the water formed was removed azeiotropically.  The progress of the reaction was 
checked by TLC using toluene: ethyl acetate (4:1) as an eluent.  After completion of the reaction, 
solvent was removed by distillation to give solid, which was filtered, and recrystallized from ethyl 
alcohol to give pure compound 4 as yellow solid; yield 74%; m.p. 186-188 
oC; IR (KBr): ν 3052 (C-H, 
Ar), 2988 (C-H, ali), 1625  (C=N),  1610 (C=N),  1070 (C-O-C),  714 (C-H, furan) cm
-1; 
1H NMR 
(DMSO-d6): δ 8.76 (s, 2H, CH), 7.70 (d, J = 7.6 Hz, 4H, ArH), 7.59 (s, 2H, ArH), 7.55-7.50 (m, 4H, 
ArH), 7.00 (d, J = 7.6 Hz, 4H, ArH), 4.12 (s, 2H, CH2), 2.44 (s, 6H, CH3), 2.21 (s, 6H, CH3); 
13C 
NMR (DMSO-d6): δ 165.3 (thiadiazole-C2), 162.7, 161.4 (thiadiazole-C5), 154.1 (C=N), 150.6 (furan-
C3b), 143.4 (furan-C2), 135.6, 135.0, 133.9 (furan C3a), 131.7, 129.6, 128.7, 126.4, 122.8, 118.5 (furan-
C3), 42.0 (CH2), 20.7 (CH3), 9.7 (CH3); MS: m/z (%) 678 (M
+, 27), 550 (32), 458 (20), 436 (37), 392 
(40), 302 (75), 102 (100). Anal. Calcd for C39H30N6O2S2: C, 69.01; H, 4.45; N, 12.38.  Found: C, 
68.95; H, 4.40; N, 12.33. 
 
Synthesis  of  bis-[3-[5-(3-methylbenzo[b]furan-7-yl)-1,3,4-thiadiazol-2-yl]-2-(4-methyl- 
phenyl)-1,3-thiazo- lan-4-one]methane (5): A mixture of compound 4 (5 mmol), thioglycolic acid 
(12 mmol) in N, N-dimethylformamide (40 mL) with a pinch of anhydrous ZnCl2, was refluxed for 6 
h, the progress of the reaction was checked by TLC using toluene: ether (3:1) as an eluent.  The 
reaction mixture was cooled to room temperature and then poured into crussed ice.  It was set-aside at 
room temperature overnight. The solid thus separated was filtered, washed several times with water, 
and purified by column chromatography on silica-gel with hexane-ethyl acetate as eluent to afford 
pure compound 5 as brown solid; yield 71%; m.p. 210-212 
oC; IR (KBr): ν 3062 (C-H, Ar), 1698 
(C=O), 1612  (C=N),  1604 (C=N),  1475 (C-N), 1066 (C-O-C),  712  (C-H,  furnan) cm
-1; 
1H NMR 
(DMSO-d6): δ
  7.64 (s, 2H, ArH), 7.49 (s, 2H, ArH), 7.25-7.19 (m, 6H, ArH), 7.10 (d, J = 7.9 Hz, 4H, 
ArH), 5.94 (s, 2H, CH), 4.20 (s, 2H, CH2), 3.70-3.67 (m, 4H, CH2), 2.36 (s, 6H, CH3), 2.24 (s, 6H, 
CH3); 
13C NMR (DMSO-d6): δ 173.2 (thiadiazole-C5), 170.6 (C=O), 154.9 (thiadiazole-C2), 150.8 
(furan-C3a), 142.9 (furan-C2), 137.9, 135.2, 135.0, 132.0 (furan-C3a), 127.4, 126.9, 125.8, 124.6, 123.7, 
118.9  (furan-C3),  72.0  (thiazolidinoe-C5),  42.0  (CH2),  33.9  (thiazolidinone-C2),  22.1  (CH3),  9.20 64 
Bis-[thiadiazol-2-yl-tetrahydro-2H-pyrazolo[3,4-d][1,3]thiazole]methanes  
 
(CH3); MS: m/z (%) 828 (M
+, 10), 784 (20), 586 (32), 451 (42), 334 (75), 214 (100). Anal. Calcd for 
C43H34N4O4S4: C, 62.45; H, 4.14; N, 10.16.  Found: C, 62.90; H, 4.10; N, 10.11. 
 
Synthesis  of  bis-[3-[5-(3-methylbenzo[b]furan-7-yl)-1,3,4-thiadiazol-2-yl]-2-(4-methyl- 
phenyl)-5-[(Z)-1-(aryl)methylidene]-1,3-thiazolan-4-one]methane    (6):  A  mixture  of 
compound 5 (5 mmol), 4-methylbenzaldehyde (10 mmol) and sodium acetate (5 mmol) in anhydrous 
glacial acetic acid (10 mL), was refluxed for 6 h. The reaction mixture was concentrated and then 
poured into ice cold water, the solid thus separated, was filtered, washed with water, the crude product 
thus obtained was purified by column chromatography on silica gel with hexane-ethyl acetate as eluent 
to afford pure compounds 6 as brown solid; yield 83%; m.p. 184-186 
oC; IR (KBr): ν 3056 (C-H, Ar), 
2942 (C-H, ali), 1720 (C=O), 1610 (C=C), 1604 (C=N), 1360 (N-C-S), 1270 (c-N), 1066 (C-O-C), 
715 (C-H, furan) cm
-1; 
1H NMR (300 MHz, DMSO-d6): δ 7.80 (s, 2H, CH=C), 7.64 (s, 2H, ArH), 
7.57-7.54 (m, 6H, ArH), 7.35-7.25 (m, 10H, ArH), 7.10 (d, J = 7.9 Hz, 4H, ArH), 6.65 (s, 2H, CH-S), 
4.17 (s, 2H, CH2), 2.51 (s, 6H, CH3), 2.40 (s, 6H, CH3), 2.22 (s, 6H, CH3); 
13C NMR (75 MHz, 
DMSO-d6): δ 172.6 (thiadiazole-C5), 164.2 (C=O), 154.5 (thiadiazole-C2), 149.5 (furan-C3b), 143.4 
(furan-C2), 139.7, 136.7, 136.1, 134.9, 134.0, 132.9, 132.4, 131.2 (furan-C3a), 129.4, 128.1, 126.7, 
126.1, 125.2 (thiazolidinone-C2), 124.8, 124.6, 116.4 (furan-C3), 72.1 (thiazolidinone-C5), 43.4, 22.9, 
22.0, 9.2; MS: m/z (%) 1032 (M
+, 12), 676 (14), 694 (40), 692 (100), 192 (30). Anal. Calcd for 
C59H46N6O4S4: C, 68.71; H, 4.50; N, 8.15.  Found: C, 68.66; H, 4.45; N, 8.12. 
 
General  procedure  for  the  synthesis  of  bis-[thiadiazol-2-yl-tetrahydro-2H-pyrazolo[3,4-
d][1,3]thiazole]methanes  (7a-h):A  mixture  of  compound  6  (5  mmol),  aryl/alkyl 
hydrazinehydrochloride (10 mmol) and anhydrous sodium acetate (5 mmol) in glacial acetic acid (20 
mL), was refluxed for 8 h. The reaction mixture was concentrated and cooled to room temperature, the 
solid thus separated, was filtered, washed thoroughly with water, the crude product thus obtained was 
purified by column chromatography on silica gel with hexane-ethyl acetate as eluent to afford pure 
compounds.  All the products were characterized by IR, 
1H, 
13C NMR, MS and elemental analyses. 
 
Bis-[6-[5-(3-methylbenzo[b]furan-7-yl)-1,3,4-thiadiazol-2-yl]-3,5-di(4-methylphen-yl)-
3,3a,5,6-tetrahy- dro-2H-pyrazolo[3,4-d][1,3]thiazole]methane (7a):
 Brown solid; Yield 69%; 
m.p. 196-198 
oC; IR (KBr): ν 3400-3300 (N-H), 3078 (C-H, Ar), 2947 (C-H, ali), 1604 (C=N), 1598 
(C=N), 1065 (C-O-C), 710 (C-H, furan) cm
-1; 
1H NMR (300 MHz, DMSO-d6): δ 7.66 (m, 4H, ArH, 
N-CH-S), 7.58 (s, 2H, ArH), 7.49 (s, 2H, ArH), 7.38 (d, J = 8.0 Hz, 4H, ArH), 7.20 (d, J = 7.8 Hz, 4H, 
ArH), 7.11 (m, 8H, ArH), 5.61 (bs, 2H, NH), 5.18 (d, J = 1.9 Hz, 2H, CH-N), 4.31 (d, J = 1.9 Hz, 2H, 
CH-S), 4.18 (s, 2H, CH2), 2.47 (s, 6H, CH3), 2.31 (s, 6H, CH3), 2.22 (s, 6H, CH3);  
13C NMR (75 
MHz,  DMSO-d6):  δ  166.9  (thiadiazole-C5),  157.6  (thiadiazole-C2),  152.4  (furan-C3a),  150.6 
(thiazolopyrazole-C2b), 141.7 (furan-C2), 139.3, 138.0, 136.9, 133.7, 132.0, 130.0 (furan-C3b), 129.1, 
128.9,  128.2,  128.0,  127.5,  125.1,  123.0,  117.9  (furan-C3),  67.1  (thiazolopyrazole-C2),  56.3 
(thiazolopyrazole-C2a), 52.0 (thiazolopyrazole-C6), 42.0 (CH2), 22.1 (CH3), 21.0 (CH3), 9.7 (CH3); 
MS: m/z (%) 1061 (M
+ +1, 21), 708 (47), 694 (72), 192 (100). Anal. Calcd for C59H50N10O2S4: C, 
66.89; H, 4.76; N, 13.22.  Found: C, 66.82; H, 4.72; N, 13.19. 
 
Bis-[  6-[5-(3-methylbenzo[b]furan-7-yl)-1,3,4-thiadiazol-2-yl]-3,5-di(4-methylphen-  yl)-2-
phenyl-3,3a,5,6-tetrahydro-2H-pyrazolo[3,4-d][1,3]thiazole]methane (7b): Black solid; Yield 
70%; m.p. 210-212 
oC; IR (KBr): ν  3065 (C-H, ArH), 2982 (C-H, ali), 1604 (C=N), 1598 (C=N), 
1061 (C-O-C), 710 (C-H, furan) cm
-1; 
1H NMR (300 MHz, DMSO-d6): δ 7.66 (s, 2H, ArH), 7.58 (s, 
2H, ArH), 7.42 (m, 4H, ArH, N-CH-S), 7.38 (d, J = 8.0 Hz, 4H, ArH), 7.20-7.15 (m, 22H, ArH), 5.18 
(d, J = 1.9 Hz, 2H, CH-S), 4.31 (d, J = 1.9 Hz, 2H, CH-S), 4.18 (s, 2H, CH2), 2.47 (s, 6H, CH3), 2.31 
(s, 6H, CH3), 2.22 (s, 6H, CH3);  
13C NMR (75 MHz, DMSO-d6): δ 166.9 (thiadiazole-C5), 158.1 
(thiadiazole-C2),  152.4  (furan-C3a),  146.2  (thiazolopyrazole-C2b),  141.7  (furan-C2),  139.0,  138.0, 
136.8, 133.7, 132.0, 130.1 (furan-C3b), 129.9, 129.2, 128.6, 128.2, 128.0, 127.3, 125.2, 123.2, 118.7, 65 
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117.9  (furan-C3),  113.6,  72.1  (thiazolopyrazole-C2),  59.6  (thiazolopyrazole-C2a),  54.9 
(thiazolopyrazole-C6), 42.0 (CH2), 22.1 (CH3), 20.7(CH3), 9.7 (CH3); MS: m/z (%) 1212 (M
+, 34)
 , 
1135 (51), 1058 (22), 694 (10), 436 (32), 334 (100).  Anal. Calcd for C71H58N10O2S4: C, 70.39; H, 
4.83; N, 11.56.  Found: C, 70.43; H, 4.80; N, 11.50. 
Black solid; Yield 72%; m.p. 214-216 
oC; IR (KBr): ν  3065 (C-H, Ar), 2982 (C-H, ali), 1604 (C=N)  
 
Bis-[2-(4-methoxyphenyl)-6-[5-(3-methylbenzo[b]furan-7-yl)-1,3,4-thiadiazol-2-yl]-3,5-di(4-
methylphenyl)-3,3a,5,6-tetrahydro-2H-pyrazolo[3,4-d][1,3]thiazole]methane  (7c):,  1598 
(C=N), 1070 (C-O-C), 1061 (C-O-C), 710 (C-H, furan) cm
-1; 
1H NMR (300 MHz, DMSO-d6): δ 7.66 
(s, 2H, ArH), 7.58 (s, 2H, ArH), 7.42 (m, 4H, ArH, N-CH-S), 7.38 (d, J = 8.0 Hz, 4H, ArH), 7.20-7.15 
(m, 8H, ArH), 7.10-6.95 (m, 12H, ArH), 5.18 (d, J = 1.9 Hz, 2H, CH-S), 4.31 (d, J = 1.9 Hz, 2H, CH-
S), 4.18 (s, 2H, CH2), 3.72 (s, 6H, OCH3), 2.47 (s, 6H, CH3), 2.31 (s, 6H, CH3), 2.22 (s, 6H, CH3); 
13C 
NMR (75 MHz, DMSO-d6): δ 166.9 (thiadiazole-C5), 158.1 (thiadiazole-C2), 155.4, 152.3 (furan-C3b), 
141.7 (thiazolopyrazole-C2b), 140.1 (furan-C2), 139.0, 138.3, 136.8, 133.7, 132.0, 130.1 (furan-C3b), 
129.2, 128.6, 128.2, 128.0, 127.3, 125.1, 123.2, 121.3, 117.9 (furan-C3), 113.4, 73.3 (thiazolopyrazole-
C2), 59.6 (thiazolopyrazole-C2a), 55.9, 54.9 (thiazolopyrazole-C6), 42.0 (CH2), 22.1 (CH3), 20.7 (CH3), 
9.6 (CH3); MS: m/z (%) 1273 (M
+ +1, 27), 1242 (10), 1058 (35), 1002 (10), 436 (21), 421( 30), 334 
(55), 102 (100).  Anal. Calcd for C73H62N10O4S4: C, 68.95; H, 4.91; N, 11.02.  Found: C, 68.90; H, 
4.86; N, 10.97. 
 
Bis-[2-(4-chlorophenyl)-6-[5-(3-methylbenzo[b]furan-7-yl)-1,3,4-thiadiazol-2-yl]-3,5-di(4-
methylphenyl)-3,3a,5,6-tetrahydro-2H-pyrazolo[3,4-d][1,3]thiazole]methane  (7d):  Brown 
solid; Yield 71%; m.p. 236-238 
oC; IR (KBr): ν  3061 (C-H, Ar), 2982 (C-H, ali), 1604 (C=N), 1598 
(C=N), 1070 (C-O-C), 710 (C-H, furan), 685 (C-Cl) cm
-1; 
1H NMR (300 MHz, DMSO-d6): δ 7.66 (s, 
2H, ArH), 7.58 (s, 2H, ArH), 7.46 (d, J = 8.4 Hz, 4H, ArH), 7.42 (m, 4H, ArH, N-CH-S), 7.38 (d, J = 
8.0 Hz, 4H, ArH), 7.20-7.15 (m, 12H, ArH), 7.10 (d, J = 7.8 Hz, 4H, ArH), 5.18 (d, J = 1.9 Hz, 2H, 
CH-S), 4.31 (d, J = 1.9 Hz, 2H, CH-S), 4.18 (s, 2H, CH2), 2.47 (s, 6H, CH3), 2.31 (s, 6H, CH3), 2.22 
(s, 6H, CH3); 
13C NMR (75 MHz, DMSO-d6): δ 166.9 (thiadiazole-C5), 157.6 (thiadiazole-C2), 152.0 
(furan-C3a), 149.2 (thiazolopyrazole-C2b), 141.7 (furan-C2), 139.0, 138.0, 136.8, 133.7, 132.0, 131.1, 
130.1 (furan-C3b), 129.9, 129.0, 128.6, 128.2, 128.0, 127.3, 125.3, 124.0, 123.2, 117.9 (furan-C3), 72.1 
(thiazolopyrazole-C2), 59.6 (thiazolopyrazole-C2a), 54.9 (thiazolopyrazole-C6), 42.0 (CH2), 22.1 (CH3), 
20.7 (CH3), 9.6 (CH3); MS: m/z (%) 1280 (M
+, 23), 1058 (33), 898 (22), 794 (54), 694 (53), 192 (75), 
102 (100).  Anal. Calcd for C71H56Cl2N10O2S4: C, 66.60; H, 4.41; N, 10.94.  Found: C, 66.66; H, 4.45; 
N, 10.92.
 
 
Bis-[  2-(3-fluorophenyl)-6-[5-(3-methylbenzo[b]furan-7-yl)-1,3,4-thiadiazol-2-yl]-3,  5-di(4-
methylphenyl)-3,3a,5,6-tetrahydro-2H-pyrazolo[3,4-d][1,3]thiazole]methane  (7e):  Brown 
solid; Yield 76%; m.p. 200-202 
oC; IR (KBr): ν 3081 (C-H, Ar), 2985 (C-H, ali), 1605 (C=N), 1599 
(C=N), 1068 (C-O-C), 710 (C-H, furan), cm
-1; 
1H NMR (300 MHz, DMSO-d6): δ 7.66 (s, 2H, ArH), 
7.58 (s, 2H, ArH), 7.42 (m, 4H, ArH, N-CH-S), 7.38 (m, 6H, ArH), 7.20-7.15 (m, 8H, ArH), 7.10 (d, J 
= 7.8 Hz, 4H, ArH), 6.65-6.55 (m, 6H, ArH), 5.18 (d, J = 1.8 Hz, 2H, CH-S), 4.31 (d, J = 1.8 Hz, 2H, 
CH-S), 4.18 (s, 2H, CH2), 2.47 (s, 6H, CH3), 2.31 (s, 6H, CH3), 2.22 (s, 6H, CH3); 
13C NMR (75 MHz, 
DMSO-d6):  δ  166.9  (thiadiazole-C5),  159.9,  158.2  (thiadiazole-C2),  152.1  (furan-C3a),  142.3 
(thiazolopyrazole-C2b), 141.7 (furan-C2), 139.1, 138.3, 136.8, 133.7, 132.0, 131.8, 130.1 (furan-C3b), 
129.2,  128.6,  128.2,  128.0,  127.3,  125.1,  123.1,  118.6,  117.9  (furan-C3),  110.4,  108.8,  72.1 
(thiazolopyrazole-C2), 59.6 (thiazolopyrazole-C2a), 54.7 (thiazolopyrazole-C6), 42.0 (CH2), 22.1 (CH3), 
20.7 (CH3), 9.7 (CH3); MS: m/z (%) 1248 (M
+, 29), 1034 (21), 795 (43), 694 (72), 192 (100).  Anal. 
Calcd for C71H56F2N10O2S4: C, 68.36; H, 4.52; N, 11.23.  Found: C, 66.42; H, 4.50; N, 11.18. 
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Bis-[2-benzyl-6-[5-(3-methylbenzo[b]furan-7-yl)-1,3,4-thiadiazol-2-yl]-3,5-di(4-meth- 
ylphenyl)-3,3a,5,6-tetrahydro-2H-pyrazolo[3,4-d][1,3]thiazole]methane  (7f):  Black  solid; 
Yield 69%; m.p. 194-196 
oC; IR (KBr): ν 3081(C-H, Ar), 2985 (C-H, ali), 1605 (C=N), 1599 (C=N), 
1068 (C-O-C), 710 (C-H, furan) cm
-1; 
1H NMR (300 MHz, DMSO-d6): δ 7.66 (s, 2H, ArH), 7.58 (s, 
2H, ArH), 7.42 (m, 4H, ArH, N-CH-S), 7.38 (m, 8H, ArH), 7.20-7.15 (m, 16H, ArH), 7.10 (d, J = 7.8 
Hz, 4H, ArH), 5.00 (d, J = 1.8 Hz, 2H, CH-S), 4.00 (d, J = 1.8 Hz, 2H, CH-S), 4.18 (s, 2H, CH2), 4.08 
(s, 2H, CH2), 2.47 (s, 6H, CH3), 2.31 (s, 6H, CH3), 2.22 (s, 6H, CH3); 
13C NMR (75 MHz, DMSO-d6): 
δ 166.8 (thiadiazole-C5), 158.2 (thiadiazole-C2), 152.4 (furan-C3a), 141.7 (thiazolopyrazole-C2b), 139.0 
(furan-C2), 138.0, 136.9, 136.2, 133.7, 132.0, 130.1 (furan-C3b), 129.2, 129.0, 128.6, 128.1, 128.0, 
127.9,  127.3,  126.0,  125.1,  123.0,  117.9  (furan-C3),  72.0  (thiazolopyrazole-C2),  59.6 
(thiazolopyrazole-C2a),  56.1,  54.8  (thiazolopyrazole-C6),  42.0  (CH2),  22.1  (CH3),  20.7  (CH3),  9.6 
(CH3); MS: m/z (%) 1240 (M
+, 33), 1149 (38), 1058 (20), 794 (41), 692 (56), 192 (100).  Anal. Calcd 
for C73H62N10O2S4: C, 70.73; H, 5.04; N, 11.30.  Found: C, 70.70; H, 5.00; N, 11.36. 
 
Bis-[2-isopropyl-6-[5-(3-methylbenzo[b]furan-7-yl)-1,3,4-thiadiazol-2-yl]-3,5-di(4-
methylphenyl)-3,3a,5,6-tetrahydro-2H-pyrazolo[3,4-d][1,3]thiazole]methane  (7g):  Brown 
solid; Yield 74%; m.p. 222-224 
oC; IR (KBr): ν 3082 (C-H, Ar), 2980 (C-H, ali), 1610 (C=N), 1600 
(C=N), 1069 (C-O-C), 711 (C-H, furan) cm
-1; 
1H NMR (300 MHz, DMSO-d6): δ 7.66 (s, 2H, ArH), 
7.58 (s, 2H, ArH), 7.42 (m, 4H, ArH, N-CH-S), 7.38 (d, J = 8.0 Hz, 4H, ArH), 7.20-7.15 (m, 8H, 
ArH), 7.10 (d, J = 7.8 Hz, 4H, ArH), 5.00 (d, J = 1.9 Hz, 2H, CH-S), 4.18 (s, 2H, CH2), 4.10 (d, J = 
1.9 Hz, 2H, CH-S), 3.10 (m, 2H, CH), 2.47 (s, 6H, CH3), 2.31 (s, 6H, CH3), 2.22 (s, 6H, CH3), 1.00 (d, 
12H, CH3, J=1.78); 
13C NMR (75 MHz, DMSO-d6): δ 166.6 (thiadiazole-C5), 157.4 (thiadiazole-C2), 
152.4 (furan-C3a), 141.7 (thiazolopyrazole-C2b), 139.1 (furan-C2), 138.0, 136.8, 133.7, 132.0, 130.1 
(furan-C3b), 129.2, 128.6, 128.2, 128.0, 127.3, 125.1, 123.2, 117.9 (furan-C3), 72.1 (thiazolopyrazole-
C2), 59.6, 58.6 (thiazolopyrazole-C2a), 54.8 (thiazolopyrazole-C6), 42.0, 23.6, 22.1, 20.7, 9.6; MS: m/z 
(%) 1144 (M
+, 21), 1101 (10), 1058 (27), 1022 (10), 840 (75), 692 (63), 194 (100).  Anal. Calcd for 
C65H62N10O2S4: C, 68.27; H, 5.46; N, 12.25.  Found: C, 68.20; H, 5.40; N, 12.31. 
 
Bis-[2-methyl-6-[5-(3-methylbenzo[b]furan-7-yl)-1,3,4-thiadiazol-2-yl]-3,5-di(4-meth- 
ylphenyl)-3,3a,5,6-tetrahydro-2H-pyrazolo[3,4-d][1,3]thiazole]methane  (7h):  Brown  solid; 
Yield 71%; m.p. 230-232 
oC; IR (KBr): ν 3082 (C-H, Ar), 2980 (C-H, ali), 1610 (C=N), 1600 (C=N), 
1069 (C-O-C), 711 (C-H, furan) cm
-1; 
1H NMR (300 MHz, DMSO-d6): δ 7.66 (s, 2H, ArH), 7.58 (s, 
2H, ArH), 7.42 (m, 4H, ArH, N-CH-S), 7.25-7.15 (m, 12H, ArH), 7.10 (d, J = 7.8 Hz, 4H, ArH), 4.80 
(d, J = 1.8 Hz, 2H, CH-S), 4.18 (s, 2H, CH2), 4.10 (d, J = 1.8 Hz, 2H, CH-S), 2.70 (s, 6H, N-CH3), 
2.47 (s, 6H, CH3), 2.31 (s, 6H, CH3), 2.22 (s, 6H, CH3); 
13C NMR (75 MHz, DMSO-d6): δ 166.4 
(thiadiazole-C5), 157.9 (thiadiazole-C2), 152.4 (furan-C3a), 141.7 (thiazolopyrazole-C2b), 139.0 (furan-
C2), 138.0, 136.8, 133.7, 132.0, 130.1 (furan-C3b), 129.2, 128.6, 128.1, 128.1, 127.3, 125.1, 123.2, 
117.9 (furan-C3), 72.0 (thiazolopyrazole-C2), 59.6 (thiazolopyrazole-C2a), 54.8 (thiazolo pyrazole-C6), 
42.0 (CH2), 38.4 (CH3), 22.1 (CH3), 20.7 (CH3), 9.6 (CH3); MS: m/z (%) 1089 (M
+ 39), 1003 (10), 795 
(42), 634 (55), 692 (73), 192 (100).  Anal. Calcd for C61H54N10O2S4: C, 67.38; H, 5.01; N, 12.88.  
Found: C, 67.30; H, 5.08; N, 12.82. 
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